分泌性白细胞肽酶抑制剂与肿瘤关系的研究进展  

Research Progress of Relation between Secretory Leukocyte Peptidase Inhibitor and Tumor

作　　者：沈萍萍[1] 黄智铭[1] 

机构地区：[1]温州医学院附属第一医院消化内科,浙江温州325000

出　　处：《医学综述》2010年第2期213-215,共3页Medical Recapitulate

摘　　要：分泌性白细胞肽酶抑制剂属于Kazal型-丝氨酸蛋白酶抑制剂家族,其与肿瘤发生发展、生物学行为及其预后有较密切的关系,而成为研究热点。在卵巢癌、非小细胞性肺癌、胃癌等均有表达,且与肿瘤的发生、发展相关。然而,到目前为止,分泌性白细胞肽酶抑制剂在肿瘤中的作用仍然存在争议。探讨其在肿瘤及抗肿瘤中的作用及可能的肿瘤发生、发展机制,将有助于肿瘤的防治及对疾病预后的判断。Secretory leukocyte peptidase inhibitor （SLPI）belonged to Kazal-type serpin family, which become a research hotspot because of its close relation with the occurrence and development, biological behaviour and prognosis of tumor. SLPI was expressed in ovarian cancer, non-small cell lung carcinoma and gastric cancer,and it had close relation with the occurrence and development of tumor. However,the effect of SLPI in tumor exist dispute until now, The research of its effect in tumor, anti-tumor and its possible development in tumor will be helpful to the prevention of cancer and the disease prognostic judgement.

关 键 词：分泌性白细胞肽酶抑制剂 肿瘤 消化道肿瘤 

分 类 号：R73[医药卫生—肿瘤]